Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus

Journal of Clinical Microbiology

Volumn 44, Issue 8, 2006, Pages 2785-2791

  Asha, N J ^a   Tompkins, D ^b   Wilcox, M H ^a,c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTACID AGENT; CEPHALOSPORIN DERIVATIVE; CLOSTRIDIUM DIFFICILE CYTOTOXIN; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN; CYTOTOXIC AGENT; CYTOTOXIN; ENTEROTOXIN; MACROLIDE; METRONIDAZOLE; PENICILLIN DERIVATIVE; PENICILLIN G; PENICILLIN V; SULFONAMIDE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ANTIBIOTIC ASSOCIATED DIARRHEA; ARTICLE; BACTERIAL GROWTH; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; DIARRHEA; FEEDING APPARATUS; FEMALE; GENDER; GENE CLUSTER; GENOTYPE; GEOGRAPHY; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REINFECTION; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE; STRAIN IDENTIFICATION; VERO CELL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANIMALS; ANTACIDS; BACTERIAL TOXINS; CERCOPITHECUS AETHIOPS; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; CLUSTER ANALYSIS; CROSS INFECTION; DNA FINGERPRINTING; DNA, BACTERIAL; ENTERAL NUTRITION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGY, MOLECULAR; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; RISK FACTORS; SEX FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STATISTICS; VERO CELLS;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; STAPHYLOCOCCUS AUREUS;

EID: 33747173404     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00165-06     Document Type: Article

References (49)

1. Asha, N. J., and M. H. Wilcox. 2002. Laboratory diagnosis of Clostridium perfringens antibiotic-associated diarrhoea. J. Med. Microbiol. 51:891-894.
2. Bannerrnan. T. L., G. A. Hancock, F. C. Tenover, and J. M. Miller. 1995. Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus. J. Clin. Microbiol. 33:551-555.
3. Bartlett, J. G., T. W. Chang, M. Gurwith, S. L. Gorbach, and A. B. Onderdonk. 1978. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N. Engl. J. Med. 298:531-534.
4. Beaugerie, L., and J. C. Petit. 2004. Microbial-gut interactions in health and disease. Antibiotic-associated diarrhoea. Best Pract. Res. Clin. Gastroenterol. 18:337-352.
5. Bliss, D. Z., S. Johnson, K. Savik, C. R. Clabots, K. Willard, and D. N. Gerding. 1998. Acquisition of Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann. Intern. Med. 129:1012-1019.
6. Boriello, S. P., and R. K. T. Williams. 1985. Treatment of Clostridium perfringens enterotoxin-associated diarrhoea with metronidazole. J. Infect. 10:65-67.
7. Borriello, S. P., F. E. Barclay, A. R. Welch, et al. 1985. Epidemiology of diarrhoea caused by enterotoxigenic Clostridium perfringens. J. Med. Microbiol. 20:363-372.
8. Borriello, S. P., H. E. Larson, A. R. Welch, F. Barclay, M. F. Stringer, and B. A. Bartholomew. 1984. Enterotoxigenic Clostridium perfringens: a possible cause of antibiotic-associated diarrhoea. Lancet i:305-307.
9. Brett, M. M. 1998. Kits for the detection of some bacterial food poisoning toxins: problems, pitfalls and benefits. J. Appl. Microbiol. 84(Suppl.):110-118.
10. Cunningham, R., B. Dale, B. Undy, and N. Gaunt. 2003. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J. Hosp. Infect. 54:243-245.
11. Dial, S., J. A. C. Delaney, A. D. Barkun, and S. Suissa. 2005. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294:2989-2995.
12. Fawley, W. N., J. Freeman, and M. H. Wilcox. 2003. Evidence to support the existence of subgroups within the UK epidemic Clostridium difficile strain (PCR ribotype 1). J. Hosp. Infect. 54:74-77.
13. Fawley, W. N., and M. H. Wilcox. 2001. Molecular epidemiology of endemic Clostridium difficile infection. Epidemiol. Infect. 126:343-350.
14. Forward, L. J., D. S. Tompkins, and M. M. Brett. 2003. Detection of Clostridium difficile cytotoxin and Clostridium perfringens enterotoxin in cases of diarrhoea in the community. J. Med. Microbiol. 52:753-757.
15. Freeman, J., F. J. O'Neill, and M. H. Wilcox. 2003. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J. Antimicrob. Chemother. 52:96-102.
16. Freeman, J., and M. H. Wilcox. 1999. Antibiotics and Clostridium difficile. Microbes Infect. 1:377-384.
17. Froberg, M. K., E. Palavecino, R. Dykoski, D. N. Gerding, L. R. Peterson, and S. Johnson. 2004. Staphylococcus aureus and Clostridium difficile cause distinct pseudomembranous intestinal diseases. Clin. Infect. Dis. 39:747-750.
18. Gerding, D. N. 2004. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin. Infect. Dis. 38:646-648.
19. Gravel, A., M. Rondeau, C. Harf-Monteil, F. Grunenberger, H. Monteil, J.-M. Scheftel, and G. Prévost. 1999. Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and bicomponent toxin LukE-LukD. J. Clin. Microbiol. 37:4012-4019.
20. Halim, H. A., G. M. Peterson, W. T. Friesen, and A. K. Ott. 1997. Case-controlled review of Clostridium difficile-associated diarrhoea in Southern Tasmania. J. Clin. Pharm. Ther. 22:391-397.
21. Hancock, P. 1997. Antibiotic-associated diarrhoea: Clostridium difficile or C. perfringens? Rev. Med. Microbiol. 8(Suppl. 1):66-67.
22. Johnson, S., and D. N. Gerding. 1997. Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 26:1027-1036.
23. Kyne, L., C. Merry, B. O'Connell, A. Kelly, C. Keane, and D. O'Neill. 1999. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing 28:107-113.
24. Kyne, L., S. Sougioultzis, L. V. McFarland, and C. P. Kelly. 2002. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect. Control Hosp. Epidemiol. 23:653-659.
25. Kyne, L., M. Warny, A. Qamar, and C. P. Kelly. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-397.
26. Larson, H. E., A. B. Price, P. Honour, and S. P. Borriello. 1978. Clostridium difficile and the aetiology of pseudomembraneous colitis. Lancet i:1063-1066.
27. Ludlam, H., N. Brown, O. Sule, C. Redpath, N. Coni, and G. Owen. 1999. An antibiotic policy associated with reduced risk of Clostridium difficile-associated diarrhoea. Age Ageing 28:578-580.
28. Maslanka, S. E., J. G. Kerr, G. Williams, J. M. Barbaree, L. A. Carson, J. M. Miller, and B. Swaminathan. 1999. Molecular subtyping of Clostridium perfringens by pulsed-field gel electrophoresis to facilitate food-borne-disease outbreak investigations. J. Clin. Microbiol. 37:2209-2214.
29. McDonald, M., P. Ward, and K. Harvey. 1982. Antibiotic-associated diarrhoea and methicillin-resistant Staphylococcus aureus. Med. J. Aust. 1:462-464.
30. McFarland, L. V., C. M. Surawicz, and W. E. Stamm. 1990. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J. Infect. Dis. 162:678-684.
31. McFarland, L. V. 1995. Epidemiology of infectious and iatrogenic nosocomial diarrhea in a cohort of general medicine patients. Am. J. Infect. Control 23:295-305.
32. McFarland, L. V. 1998. Epidemiology, risk factors and treatment for antibiotic-associated diarrhea. Dig. Dis. 16:292-307.
33. McLauchlin, J., G. Ripabelli, M. M. Brett, and E. J. Threlfall. 2000. Amplified fragment length polymorphism (AFLP) analysis of Clostridium perfringens for epidemiological typing. Int J. Food Microbiol. 56:21-28.
34. McLauchlin, J., J. E. Salmon, S. Ahmed, et al. 2002. Amplified fragment length polymorphism (AFLP) analysis of Clostridium novyi, C. perfringens and Bacillus cereus isolated from injecting drug users during 2000. J. Med. Microbiol. 51:990-1000.
35. McNulty, C., M. Logan, I. P. Donald, D. Ennis, D. Taylor, R. N. Baldwin, M. Bannerjee, and K. A. Cartwright. 1997. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J. Antimicrob. Chemother. 40:707-711.
36. Nelson, D. E., S. B. Auerbach, A. L, Baltch, et al. 1994. Epidemic Ciostridium difficile-associated diarrhea: role of second- and third-generation cephalosporins. Infect. Control Hosp. Epidemiol. 15:88-94.
37. Parker, M. T. 1972. Phage-typing of Staphylococcus aureus. p. 1-28. In J. R. Norris and D. W. Ribbons (ed.), Methods in microbiology, vol. 7B. Academic Press, London, United Kingdom.
38. Ransome, N. J. P. Fitzgerald, and M. H. Wilcox. 1998. Antibiotic-associated diarrhea and Clostridium perfringens enterotoxin, abstr. K-126. Program Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., San Diego, Calif.
39. Samore, M. H., L. Venkataraman, P. C. DeGirolami, R. D. Arbeit, and A. W. Karchmer. 1996. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am. J. Med. 100:32-40.
40. Schalch, B., J. Björkroth, H. Eisgruber, H. Korkeala, and A. Stolle. 1997. Ribotyping for strain characterization of Clostridium perfringens isolates from food poisoning cases and outbreaks. Appl. Environ Microbiol. 63:3992-3994.
41. Settle, C. D., M. H. Wilcox, W. N. Fawley, O. J. Corrado, and P. M. Hawkey. 1998. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin- tazobactam. Aliment. Pharmacol. Ther. 12:1217-1223.
42. Spencer, R. C. 1998. Clinical impact and associated costs of Clostridium difficife-associated disease. J. Antimicrob. Chemother. 41(Suppl. C):5-12.
43. Tenover, F. C., R. D. Arbeit, and R. V. Goering. 1997. How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologists. Infect. Control Hosp. Epidemiol. 18:426-439.
44. Thomas, C., M. Stevenson, and T. V. Riley. 2003. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J. Antimicrob. Chemother. 51:1339-1350.
45. Wada, A., Y. Masuda, M. Fukayama, T. Hatakeyama, Y. Yanagawa, H. Watanabe, and T. Inamatsu. 1996. Nosocomial diarrhoea in the elderly due to enterotoxigenic Clostridium perfringens. Microbiol. Immunol. 40:767-771.
46. Wilcox, M. H., W. N. Fawley, and P. Parnell. 2000. Value of lysozyme agar incorporation and alkaline thioglycollate exposure for the environmental recovery of Clostridium difficile. J. Hosp. Infect. 44:65-69.
47. Wilcox, M. H., J. Freeman, W. Fawley, S. MacKinlay, A. Brown, K, Donaldson, and O. Corrado. 2004. Long-term surveillance of cefotaxime and piperacillintazobactam prescribing and incidence of Clostridium difficile diarrhoea. J. Antimicrob. Chemother. 54:168-172.
48. Wilcox, M. H. 2001. Clarithromycin and risk of Clostridium difficile-associated diarrhoea. J. Antimicrob. Chemother. 47:357-368.
49. Wood, M. 2001. When stool cultures from adult inpatients are appropriate. Lancet 357:901-902.